- Home
- TLX vs VRNS Comparison
TLX vs VRNS Comparison
Compare TLX & VRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLX | VRNS |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | Australia | United States |
| Employees | 1184 | 2658 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.3B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | TLX | VRNS |
|---|---|---|
| Price | $10.68 | $28.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 21 |
| Target Price | $21.13 | ★ $42.75 |
| AVG Volume (30 Days) | 174.5K | ★ 2.7M |
| Earning Date | 08-19-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $270,288,000.00 |
| Revenue This Year | N/A | $18.87 |
| Revenue Next Year | N/A | $17.77 |
| P/E Ratio | $150.33 | ★ N/A |
| Revenue Growth | N/A | ★ 24.35 |
| 52 Week Low | $6.28 | $19.70 |
| 52 Week High | $18.13 | $63.90 |
Technical Indicators
Market Signals| Indicator | TLX | VRNS |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 67.90 |
| Support Level | $10.60 | $20.21 |
| Resistance Level | $11.18 | $28.99 |
| Average True Range (ATR) | 0.25 | 1.45 |
| MACD | -0.07 | 0.37 |
| Stochastic Oscillator | 49.19 | 79.88 |
Price Performance
Historical ComparisonAbout TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
About VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.